Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures and neuropsychiatric disorders for both hospital and home settings.
*Delayed quote courtesy of Google Finance.
View Stock Information
Lookup Date :
- Feb 14, 2020 Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Feb 03, 2020 Marinus Pharmaceuticals to Present Ganaxolone EEG Clinical Data in Status Epilepticus at the American Clinical Neurophysiology Society 2020 Annual Meeting